ESR1 and breast cancer: 1,25-(OH)2D3 also diminishes the proliferation of breast cancer cells by inhibiting estrogen synthesis and signaling through estrogen receptor (ER)α [153] and by downregulating RAS expression and the phosphorylation of its downstream effectors MEK and ERK1/2 [154].